Phase 4Active, not recruitingHealthspan endpoint
GLP-1s to Enhance Lasting Optimal Weight (GLOW)
Tirzepatide in Obesity
Wake Forest University Health Sciences · 40 enrolled · NCT06861439 · updated 2 Oct 2026
From ClinicalTrials.gov
Clinical trials
Trials of drugs and interventions aimed at aging, of age-related conditions through aging biology, and of healthspan itself: new registrations, status changes and first results.
Phase 4RecruitingAge-related condition
Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis
Colchicine 0.5 mg orally once daily for 12 months., SoC therapy in Colchicine, Coronary Atherosclerosis Management, Clonal Hematopoiesis of Indeterminate Potential
Shenyang Northern Hospital · 120 planned · NCT07362966 · updated 1 Oct 2026